

Acute Pain Market Epidemiology Report 2025-2035: Pipeline Therapies, Drugs Sales, and Regional Outlook


The report provides a detailed analysis of the current acute pain marketed drugs and late-stage pipeline drugs.

BROOKLYN, NY, UNITED STATES, July 15, 2025 /EINPresswire.com/ -- The [acute pain market size reached a value of USD 83.5 million](#) in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 129.8 million by 2035, exhibiting a growth rate (CAGR) of 4.09% during 2025-2035.

Acute pain is abrupt and transient; it is purely physiological secondary to a noxious stimulus and typically resolves in 7 to 30 days. It has an essential biological role as a warning signal for tissue injury and is typically encountered postoperatively or with an acute injury or trauma. Though it will likely fade with time, acute pain is best treated whenever feasible since in some extreme instances, poor management of acute pain will be critical in evolving to chronicity-based pain. This forward-thinking manner of pain care that potentially avoids future pain-related complications is a shift in health philosophy at its core, where the emphasis is no longer simply on the relief of symptoms but on pain management as a component of sustained health and the prevention of disease.

New Trends in Acute Pain Management

This most important trend with a defining impact on the acute pain treatment market is the widespread global drift from traditional opioid analgesics. The consequences for such competition follow primarily due to the ongoing opioid crisis being ushered in with escalating rates of opioid use disorder, addiction, and overdose-related deaths. With time and growing awareness, regulatory agencies like the CDC have developed recommendations to restrict opioids prescriptions for acute pain, and many states have imposed their own regulations. This public health and regulatory push is a strong driver, which has forced healthcare professionals



and pharmaceutical industries to focus on developing and adopting safer, non-addictive options.

There is an increased activity in the market in terms of research and development aimed at innovative non-opioid pain drugs. A high-profile example is suzetrigine, an experimental oral non-opioid analgesic for moderate-to-severe acute pain, that was granted FDA priority review with a promised action date in early 2025. Other significant advances include dual-NMR agonists such as Cebranopadol, moving into pivotal Phase 3 clinical trials, and recent approvals of novel non-opioid analgesics like Journavx in February 2025. In addition to new chemical entities, interest is increasing in biologics and regenerative medicine, such as platelet-rich plasma (PRP) therapy and stem cell therapy, for their ability not only to minimize pain but also to drive healing, particularly in conditions involving tissue injury or inflammation. Innovation is also revolutionizing the administration of acute pain medications, with a spotlight on the intersection of drug and medical device innovation.

One significant trend is the creation of long-acting preparations, like extended-release tablets or patches, that maintain pain control for extended periods with less dosing, thus enhancing patient compliance and convenience. In the field of medical devices, neuromodulation therapies such as spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) are picking up considerable momentum as drug-free treatments for pain control. Expected developments in 2025 include the development of closed-loop neuromodulation systems that utilize artificial intelligence (AI) and bio-feedback to make real-time adjustments to stimulation and the delivery of smaller, longer-lasting implantable devices. Additionally, cryoablation probes are becoming a technological innovation for focused nerve cooling to pain reduction with effectiveness. Increasing involvement of data, AI, and digital health in customized pain management, such as telemedicine, will facilitate democratization of access and enhance treatment outcomes through real-time optimizations and predictive analyses.

Request for a sample of this report: <https://www.imarcgroup.com/acute-pain-market/requestsampl>

This report also provides a detailed analysis of the current acute pain marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Competitive Landscape with key players:

The competitive landscape of the acute pain market has been studied in the report with the detailed profiles of the key players operating in the market.

Janssen
Assertio Therapeutics
Grunenthal
Trevena
Iroko Pharmaceuticals
Vertex Pharmaceuticals
Charleston Laboratories
ESTEVE
SiteOne Therapeutics
Scilex Pharmaceuticals

Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

7 Major Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Buy the Full Acute Pain Market Epidemiology Report with TOC:
<https://www.imarcgroup.com/checkout?id=6977&method=809>

Elena Anderson
IMARC Services Private Limited
+1 631-791-1145

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/830593481>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.